Advertisement

The Development and Clinical Testing of New Anticancer Drugs at the National Cancer Institute — Example cis-Platinum (II) Diamminedichloride (NSC 119 875)

  • S. K. Carter
  • M. Goldsmith
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 48)

Abstract

The Division of Cancer Treatment (DCT) has as one of its major functions the development and clinical testing of new anticancer drugs. The Cancer Therapy Evaluation Branch of the DCT coordinates and monitors the clinical trials on these new anticancer drugs and is responsible for liaison with the Food and Drug Administration. One of the recent drugs developed and placed into clinical trial by the DCT is cis-platinum(II) diamminedichloride (NSC 119 875). The purpose of this paper is to outline the major steps in the development of a new anticancer drug with emphasis on the techniques of clinical evaluation utilizing the platinum compound as the specific example.

Keywords

Anticancer Drug Platinum Compound Platinum Drug Preclinical Development Drug Development Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dixon, R. L.: Laboratory of toxicology. Cancer Chemother. Rep. 2 (3), 61 (1971).Google Scholar
  2. 2.
    Freireich, E. J., Gehan, E. A., RALL, D. P., SCHMIDT, L. H., SKIPPER, H. E.: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219 (1966).Google Scholar
  3. 3.
    Hansen, H. H.: Clinical experience with 1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU, NSC 79 037). Proc. Amer. Ass. Cancer Res. (Abstr.) 11, 87 (1970).Google Scholar
  4. 4.
    Muggia, F. M.: Phase I study of 4’ demethyl-epipodophyllotoxin-B-D-thenylidene glycoside (PTG, NSC 122 819). Proc. Amer. Ass. Cancer Res. (Abstr.) 11, 58 (1970).Google Scholar
  5. 5.
    Pinkel, D.: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18, 853 (1958).PubMedGoogle Scholar
  6. 6.
    Rosenberg, B., Van Camp, L., Grimley, E. B., Thomson, A. J.: The inhibition of growth on cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J. biol. Chem. 242, 1347 (1967).PubMedGoogle Scholar
  7. 7.
    Rosenberg, B., Van Camp, L., Krigas, T.: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (Lond.) 205, 698 (1965).CrossRefGoogle Scholar
  8. 8.
    Rothenberg, L., Terselic, R. A.: Management of the National Cancer Institute’s drug research program through application of the linear array concept. Cancer Chemother. Rep. 54, 303 (1970).Google Scholar
  9. 9.
    Schein, P. S., DAVIS, R. D., Carter, S., Newman, J., Schein, D. R., RALL, D. A.: The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11, 3 (1970).PubMedGoogle Scholar
  10. 10.
    Shirkey, H. C.: Drug dosage for infants and children. J. Amer. med. Ass. 193, 443 (1965).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1974

Authors and Affiliations

  • S. K. Carter
  • M. Goldsmith

There are no affiliations available

Personalised recommendations